Reddy’s and Hospira lose over US Alimta
Dr Reddy’s Laboratories and Pfizer’s Hospira unit have suffered defeats in their US litigation over a vitamin regimen patent protecting Eli Lilly’s Alimta (pemetrexed disodium) injectable oncology drug. Lilly expects both of the generics companies to appeal against the ruling by the US district court for the Southern District of Indiana that the alternative salt forms of pemetrexed proposed by the generics firms would infringe US patent 7,772,209, which expires on 24 May 2022, including a six-month paediatric extension.
You may also be interested in...
FDA approval for a hybrid 505(b)(2) new drug application referencing Alimta has been awarded to Teva’s Actavis, with a key patent expiring in May 2022 proving a barrier to market entry. Teva was itself shot down over attempts to launch an ANDA product several years ago.
The US Supreme Court has refused a certiorari petition to review a decision involving Dr Reddy’s and Pfizer over Eli Lilly’s Alimta that revolved around the doctrine of equivalents.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.